These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 4514336)

  • 21. Morphological and biochemical studies on liver biopsies of parkinsonian patients treated with levodopa and decarboxylase inhibitor.
    Nevalainen T; Riekkinen P; Rinne UK; Sonninen V
    Acta Neurol Scand; 1974; 50(1):122-30. PubMed ID: 4365556
    [No Abstract]   [Full Text] [Related]  

  • 22. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 24. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.
    Marsden CD; Parkes JD; Rees JE
    Lancet; 1973 Dec; 2(7844):1459-62. PubMed ID: 4129310
    [No Abstract]   [Full Text] [Related]  

  • 25. Recent advances in the treatment of Parkinsonism with drugs.
    Rinne UK
    Acta Neurol Scand Suppl; 1972; 51():59-103. PubMed ID: 4576076
    [No Abstract]   [Full Text] [Related]  

  • 26. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 27. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H
    Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
    Marsden CD; Barry PE; Parkes JD; Zilkha KJ
    J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):10-4. PubMed ID: 4691682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma concentration of levodopa in patients with Parkinson's disease.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 10(5):301-10. PubMed ID: 4789106
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

  • 32. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL; Ringel SP
    Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
    [No Abstract]   [Full Text] [Related]  

  • 33. [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].
    Schneider E; Fischer PA; Jacobi P; Maxion H
    Arch Psychiatr Nervenkr (1970); 1973 Mar; 217(1):95-112. PubMed ID: 4695662
    [No Abstract]   [Full Text] [Related]  

  • 34. Levodopa and Ro 4-4602 in psoriasis.
    Giroux JM; Dubuc R; Barbeau A
    Lancet; 1972 Aug; 2(7772):333-4. PubMed ID: 4115065
    [No Abstract]   [Full Text] [Related]  

  • 35. Levodopa in the treatment of Parkinsonism.
    Cotzias GC
    JAMA; 1971 Dec; 218(13):1903-8. PubMed ID: 5171066
    [No Abstract]   [Full Text] [Related]  

  • 36. [Therapy of parkinsonism using L-dopa. I].
    Glass J
    Z Arztl Fortbild (Jena); 1972 Dec; 66(23):1195-9. PubMed ID: 4652156
    [No Abstract]   [Full Text] [Related]  

  • 37. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 38. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 39. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of Parkinson's disease with levodopa and Ro 4-4602.
    Barbeau A; Gillo-Joffroy L; Mars H
    Clin Pharmacol Ther; 1971; 12(2):353-9. PubMed ID: 4930866
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.